Gene therapy for recessive dystrophic epidermolysis bullosa

Dermatologic Clinics

Volumn 28, Issue 2, 2010, Pages 361-366

  Titeux, Matthias ^a,b   Pendaries, Valérie ^a,b   Hovnanian, Alain ^a,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Fibroblast; Keratinocyte; Type VII collagen; Vector

Indexed keywords

COLLAGEN TYPE 7; COLLAGEN TYPE 7 ALPHA 1; COMPLEMENTARY DNA; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; PLASMID VECTOR; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AUTOSOMAL RECESSIVE DISORDER; CELL RENEWAL; CELL THERAPY; CHROMOSOME 3P; COLLAGEN SYNTHESIS; DISEASE SEVERITY; DNA TRANSFER; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EX VIVO GENE TRANSFER; EXON; EXON SKIPPING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENE THERAPY; GENETIC CODE; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VIVO GENE TRANSFER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN QUATERNARY STRUCTURE; REVIEW; RISK BENEFIT ANALYSIS; SKIN GRAFT; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM;

COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENE THERAPY; HUMANS;

EID: 77952527820     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.02.003     Document Type: Review

References (40)

1. Mavilio F., Pellegrini G., Ferrari S., et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006, 12:1397-1402.
2. Barrandon Y., Green H. Three clonal types of keratinocyte with different capacities for multiplication. Proc Natl Acad Sci U S A 1987, 84:2302-2306.
3. Rheinwald J.G., Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6:331-343.
4. Ronfard V., Rives J.M., Neveux Y., et al. Long-term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation 2000, 70:1588-1598.
5. Llames S.G., Del Rio M., Larcher F., et al. Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 2004, 77:350-355.
6. Navsaria H.A., Myers S.R., Leigh I.M., et al. Culturing skin in vitro for wound therapy. Trends Biotechnol 1995, 13:91-100.
7. Mecklenbeck S., Compton S.H., Mejia J.E., et al. A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum Gene Ther 2002, 13:1655-1662.
8. Ortiz-Urda S., Thyagarajan B., Keene D.R., et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002, 8:1166-1170.
9. Chen M., Kasahara N., Keene D.R., et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 2002, 32:670-675.
10. Woodley D.T., Krueger G.G., Jorgensen C.M., et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003, 121:1021-1028.
11. Goto M., Sawamura D., Ito K., et al. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol 2006, 126:766-772.
12. Gache Y., Baldeschi C., Del Rio M., et al. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 2004, 15:921-933.
13. Ortiz-Urda S., Lin Q., Green C.L., et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003, 111:251-255.
14. Woodley D.T., Keene D.R., Atha T., et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004, 10:693-695.
15. Titeux M., Zanta-Boussif A., Rochat A., et al. Ex vivo gene therapy for recessive dystrophic epidermolysis bullosa using safe retroviral vectors expressing type VII collagen under the control of its promoter. J Invest Dermatol 2005, 125:110.
16. Woodley D.T., Keene D.R., Atha T., et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 2004, 10:318-326.
17. Spink J., Geddes D. Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment. Gene Ther 2004, 11:1611-1616.
18. Aartsma-Rus A., van Ommen G.J. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007, 13:1609-1624.
19. Aartsma-Rus A., Fokkema I., Verschuuren J., et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009, 30:293-299.
20. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686.
21. Goto M., Sawamura D., Nishie W., et al. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol 2006, 126:2614-2620.
22. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
23. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal t cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
24. Cornils K., Lange C., Schambach A., et al. Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther 2009, 17:131-143.
25. Maruggi G., Porcellini S., Facchini G., et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther 2009, 17:851-856.
26. Montini E., Cesana D., Schmidt M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119:964-975.
27. Dasgupta S., Navarrete A.M., Delignat S., et al. Immune response against therapeutic factor VIII in hemophilia A patients-a survey of probable risk factors. Immunol Lett 2007, 110:23-28.
28. Wang L., Cao O., Swalm B., et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005, 12:1453-1464.
29. Ghazizadeh S., Kalish R.S., Taichman L.B. Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol Ther 2003, 7:296-303.
30. Tripathy S.K., Black H.B., Goldwasser E., et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550.
31. Woodley D.T., Remington J., Chen M. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Clin Rev Allergy Immunol 2007, 33:78-84.
32. Woodley D.T., Briggaman R.A., Gammon W.R. Acquired epidermolysis bullosa. A bullous disease associated with autoimmunity to type VII (anchoring fibril) collagen. Dermatol Clin 1990, 8(4):717-726. [review].
33. Remington J., Wang X., Hou Y., et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009, 17:26-33.
34. Scofield R.H. Autoantibodies as predictors of disease. Lancet 2004, 363:1544-1546.
35. Pendaries V, Gasc G, Titeux M, et al. Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa. Gene Therapy 2010, in press.
36. Faria A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006, 13:143-157.
37. Rocino A., Santagostino E., Mancuso M.E., et al. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006, 91:558-561.
38. Eghtesad S., Morel P.A., Clemens P.R. The companions: regulatory T cells and gene therapy. Immunology 2009, 127:1-7.
39. Joffre O., Santolaria T., Calise D., et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008, 14:88-92.
40. Titeux M, Pendaries V, Zanta-Boussif MA, et al. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol Ther 2010, in press.